Pathology of benign prostatic hyperplasia
- PMID: 19002119
- DOI: 10.1038/ijir.2008.55
Pathology of benign prostatic hyperplasia
Abstract
The epidemiology of benign prostatic hyperplasia (BPH) is complex and not fully understood. The androgenic hormones testosterones and dihydrotestosterone play at least a permissive and important role. Growth factors and other hormones including estrogens may also play a role. BPH is a truely hyperplastic process resulting in growth of glandular-epithelial and stromal/muscle tissue in the prostate, leading to often measurable growth taking on different shapes and configurations which may impact symptoms and secondary outcomes. It is important to recognize that BPH is a histological conditions, which is one but not the only cause of lower urinary tract symptoms, and may or may not be associated with prostate enlargement and bladder outlet obstruction. Recognizing the different entities and determining their presence in individual patients may help with therapeutic decision making.
Similar articles
-
Clinical and experimental studies of benign prostatic hyperplasia.Urol Clin North Am. 1990 Aug;17(3):461-75. Urol Clin North Am. 1990. PMID: 1695775 Review.
-
The overlooked cause of benign prostatic hyperplasia: prostatic urethral angulation.Med Hypotheses. 2008;70(3):532-5. doi: 10.1016/j.mehy.2007.07.012. Epub 2007 Aug 29. Med Hypotheses. 2008. PMID: 17761390
-
Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.Prostate Cancer Prostatic Dis. 2005;8(3):206-9. doi: 10.1038/sj.pcan.4500806. Prostate Cancer Prostatic Dis. 2005. PMID: 15953934
-
The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.Int J Impot Res. 2008 Dec;20 Suppl 3:S19-26. doi: 10.1038/ijir.2008.53. Int J Impot Res. 2008. PMID: 19002120 Review.
-
Role of growth factors in benign prostatic hyperplasia.Eur Urol. 1997;32 Suppl 1:22-7. Eur Urol. 1997. PMID: 9218939 Review.
Cited by
-
Adreno-Muscarinic Synergy of Contractile Responses From Human Hyperplastic Prostate.Int Neurourol J. 2024 Feb;28(Suppl 1):46-54. doi: 10.5213/inj.2346144.122. Epub 2024 Feb 29. Int Neurourol J. 2024. PMID: 38461856 Free PMC article.
-
YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia.iScience. 2024 Feb 5;27(3):109125. doi: 10.1016/j.isci.2024.109125. eCollection 2024 Mar 15. iScience. 2024. PMID: 38420594 Free PMC article.
-
Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS).Prostate. 2024 Apr;84(5):417-425. doi: 10.1002/pros.24656. Epub 2024 Jan 9. Prostate. 2024. PMID: 38193363 Review.
-
Feasibility study on a new enhanced device for patients with intermittent catheterization (LUJA).J Prev Med Hyg. 2023 Nov 20;64(3 Suppl 1):E1-E89. doi: 10.15167/2421-4248/jpmh2023.64.3s1. eCollection 2023 Sep. J Prev Med Hyg. 2023. PMID: 38125911 Free PMC article. No abstract available.
-
The Predictive Value of the Systemic Immune-Inflammation Index for the Progression of Lower Urinary Tract Symptoms in Men.Asian Pac J Cancer Prev. 2023 Nov 1;24(11):3845-3850. doi: 10.31557/APJCP.2023.24.11.3845. Asian Pac J Cancer Prev. 2023. PMID: 38019242 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
